| Clinical data | |
|---|---|
| Other names | 19-Norandrostenediol; 19-Nor-4-androstene-3β,17β-diol; Estr-4-ene-3β,17β-diol; 3β-Dihydronandrolone |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C18H28O2 |
| Molar mass | 276.420 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Bolandiol (INN, also known as19-nor-4-androstenediol,estr-4-ene-3β,17β-diol, or3β-dihydronandrolone) is ananabolic-androgenic steroid (AAS) that was never marketed.[1] However, adipropionateesterderivative,bolandiol dipropionate, has been marketed.[1][2] Bolandiol and its dipropionate ester are unique among AASs in that they reportedly also possessesestrogenic andprogestogenic activity.[3][4]
Bolandiol is on theWorld Anti-Doping Agency's list of prohibited substances,[5] and is therefore banned from use in most major sports. It is a potentialmetabolic precursor (via 3β-HSD) tonandrolone or a derivative ofnandrolone (via 3β-hydroxy-steroid:NADP+ 3-oxidoreductase).[6] However, several clinical studies have concluded that bolandiol does not alter strength, body composition, or exercise performance.[7][8]